These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34831634)

  • 1. Characterization of IL-2 Stimulation and TRPM7 Pharmacomodulation in NK Cell Cytotoxicity and Channel Co-Localization with PIP
    Du Preez S; Eaton-Fitch N; Cabanas H; Staines D; Marshall-Gradisnik S
    Int J Environ Res Public Health; 2021 Nov; 18(22):. PubMed ID: 34831634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP
    Eaton-Fitch N; Cabanas H; du Preez S; Staines D; Marshall-Gradisnik S
    J Transl Med; 2021 Jul; 19(1):306. PubMed ID: 34266470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered TRPM7-Dependent Calcium Influx in Natural Killer Cells of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.
    Du Preez S; Eaton-Fitch N; Smith PK; Marshall-Gradisnik S
    Biomolecules; 2023 Jun; 13(7):. PubMed ID: 37509075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients.
    Cabanas H; Muraki K; Balinas C; Eaton-Fitch N; Staines D; Marshall-Gradisnik S
    Mol Med; 2019 Apr; 25(1):14. PubMed ID: 31014226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Cabanas H; Muraki K; Eaton N; Balinas C; Staines D; Marshall-Gradisnik S
    Mol Med; 2018 Aug; 24(1):44. PubMed ID: 30134818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients.
    Balinas C; Cabanas H; Staines D; Marshall-Gradisnik S
    J Transl Med; 2019 Dec; 17(1):401. PubMed ID: 31796045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.
    Cabanas H; Muraki K; Staines D; Marshall-Gradisnik S
    Front Immunol; 2019; 10():2545. PubMed ID: 31736966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients.
    Eaton-Fitch N; Du Preez S; Cabanas H; Muraki K; Staines D; Marshall-Gradisnik S
    J Transl Med; 2022 Feb; 20(1):94. PubMed ID: 35172836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.
    Cabanas H; Muraki K; Eaton-Fitch N; Staines DR; Marshall-Gradisnik S
    Front Immunol; 2021; 12():687806. PubMed ID: 34326841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels.
    Nguyen T; Johnston S; Clarke L; Smith P; Staines D; Marshall-Gradisnik S
    Clin Exp Immunol; 2017 Feb; 187(2):284-293. PubMed ID: 27727448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients.
    Nguyen T; Staines D; Nilius B; Smith P; Marshall-Gradisnik S
    Biol Res; 2016 May; 49(1):27. PubMed ID: 27245705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Implications of Mammalian Transient Receptor Potential Melastatin 7 in the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Review.
    Du Preez S; Cabanas H; Staines D; Marshall-Gradisnik S
    Int J Environ Res Public Health; 2021 Oct; 18(20):. PubMed ID: 34682454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients.
    Sasso EM; Muraki K; Eaton-Fitch N; Smith P; Lesslar OL; Deed G; Marshall-Gradisnik S
    Mol Med; 2022 Aug; 28(1):98. PubMed ID: 35986236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target.
    Sasso EM; Muraki K; Eaton-Fitch N; Smith P; Jeremijenko A; Griffin P; Marshall-Gradisnik S
    Front Immunol; 2024; 15():1264702. PubMed ID: 38765011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.
    Eaton N; Cabanas H; Balinas C; Klein A; Staines D; Marshall-Gradisnik S
    BMC Pharmacol Toxicol; 2018 Mar; 19(1):12. PubMed ID: 29587879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a multi-site clinical assessment of ME/CFS (MCAM) sub-study.
    Querec TD; Lin JS; Chen Y; Helton B; Kogelnik AM; Klimas NG; Peterson DL; Bateman L; Lapp C; Podell RN; Natelson BH; Unger ER;
    J Transl Med; 2023 Apr; 21(1):242. PubMed ID: 37013608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone.
    Löhn M; Wirth KJ
    J Transl Med; 2024 Jul; 22(1):630. PubMed ID: 38970055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis.
    Brenu EW; van Driel ML; Staines DR; Ashton KJ; Hardcastle SL; Keane J; Tajouri L; Peterson D; Ramos SB; Marshall-Gradisnik SM
    J Transl Med; 2012 May; 10():88. PubMed ID: 22571715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome.
    Eaton-Fitch N; du Preez S; Cabanas H; Staines D; Marshall-Gradisnik S
    Syst Rev; 2019 Nov; 8(1):279. PubMed ID: 31727160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Huth TK; Staines D; Marshall-Gradisnik S
    J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.